ClinicalTrials.gg
CompletedNCT02971891Updated Sep 14, 2023Results posted

A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

A Phase 3 interventional study of CLS006 (Furosemide) Topical Gel and Vehicle Topical Gel in Cutaneous Common Warts, sponsored by Maruho Co., Ltd.. Completed at 30 sites in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2023-09-14.

Sponsored by Maruho Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
484
Allocation
Randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Warts with a site in United States — 7 open to participants now, 10 under way, 4 of them phase 3. Warts · United States.

Enrollment
4th of 58
484 · median 80
Started
2017
with 3 others
Phase 3
11 of 59
2 open now
Registered
32nd of 59
by date
Lead sponsor
2 of 59
Maruho Co., Ltd.

Among the 59 studies in Warts with a site in United States, this one is the 4th largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2017, is one of 11 in phase 3, and was the 32nd registered.

Warts

172 studies on the registry are indexed under Warts; 36 are open to participants now.

Browse Warts studies →

Open to participants now

7 of the 59 studies in Warts with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Warts studies recruiting now, 10 (53%) set no upper age limit and 9 (47%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Warts with a site in United States, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of six (6) weeks of once daily application of Furosemide Topical Gel 0.125% (CLS006) compared to vehicle in subjects ≥ 2 years of age with nongenital cutaneous common warts (verruca vulgaris).

03

Conditions studied

  • Cutaneous Common Warts

Browse trials for

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have 1 to 6 clearly identifiable common warts located on hands feet limbs, and/or trunk

    • Each wart must measure 3 to 10 mm in their longest dimension (diameter) on the epidermal plane of the skin at baseline visit,
    • Each wart must be present for at least 4 weeks at the baseline visit,
    • Plantar, facial, subungual, and common warts in regions of a pre-existing inflammatory condition are excluded. In addition, other warts (e.g., flat, genital) are excluded.
  • Male or female subjects 2 years of age or older
  • Females of who are using a highly effective form of or females of non-childbearing potential
  • Negative in-office urine pregnancy test at Screening and Baseline
  • Subjects free of any dermatologic disorder in the treatment area
  • Subjects free of any clinically significant systemic condition which will interfere with the study assessments or increase the risk of AEs
  • Subjects willing to refrain from using other topical products in the treatment area, or prohibited medications for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Subjects who have used any wart treatments/therapies, prescription or over-the-counter, as follows:

    • Salicylic acid, cantharidin, sinecatechins (VeregenTM), simple occlusion (e.g., duct tape), and/or any other over-the-counter wart-removing products in the treatment area within 4 weeks of the Baseline Visit.
    • Cryotherapy (e.g., treatment with liquid nitrogen), carbon dioxide, electrodessication, laser, surgery, or other forms of mechanical destruction (e.g., emery boards, clippers, debriders, etc.) in the treatment area within 8 weeks of the Baseline Visit.
    • Treatment with immunotherapy (DPCP, DNCB or other), imiquimod, 5-fluorouracil,bleomycin, podophyllin or any other wart immunotherapy or treatment (e.g., Candida antigen) designed to stimulate immune response within 12 weeks of the Baseline Visit.
  • Subjects who are .
  • Subjects who have taken, within 30 days prior to the Baseline visit, or require treatment with systemic immunosuppressive or immunomodulatory medication (including oral or parenteral ) during the course of the study
  • Subjects who require ongoing treatment with oral or injectable furosemide
  • Subjects who have used an drug/device within 30 days of the Baseline visit
  • Subjects with known sensitivities to any of the investigational product ingredients including furosemide (or other sulfonamides).
  • Subjects who have a abnormality of the cardiovascular, hepatic or renal systems.
  • Subjects with clinically relevant/significant abnormal laboratory results, vital signs, , and/or physical findings at Screening and/or Baseline
  • Subjects with a chronic medical condition or clinically significant abnormal physical or laboratory finding(s) that may require the use of a prohibited medication/treatment.
  • Subjects who currently abuse alcohol or drugs or who have a history of chronic alcohol or drug abuse within the past year.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
484 participants (actual)

Study arms

  • Experimental
    CLS006 (Furosemide)

    CLS006 (Furosemide) Topical Gel, 0.125%

    Drug: CLS006 (Furosemide) Topical Gel

  • Placebo comparator
    Vehicle

    Vehicle Topical Gel

    Drug: Vehicle Topical Gel

Interventions

06

What researchers measure

Primary outcomes

  1. Difference in the Proportion of Subjects With Complete Clearance of All Treated Warts Between the Active and Vehicle at Week 18/End of Post-treatment Efficacy Evaluation.

    Time frame: Week 18

Secondary outcomes

  1. The Ratio of the Number of Cleared Warts Out of the Number of Treated Warts for Each Subject

    Time frame: Week 18

  2. Difference in the Proportion of Subjects With Complete Clearance of All Treated Warts at Week 12.

    Time frame: Week 12

  3. The Ratio of Cleared Warts to All Treated Warts for Each Subject at Week 12

    Time frame: Week 12

  4. Change From Baseline in Wart Size for Each Subject

    Time frame: Week 18

07

Results

Posted Sep 14, 2023

Participant flow

Subjects must have 1 to 6 clearly identifiable common warts located on hands, feet, limbs, and/or trunk

Participant flow — Overall Study
MilestoneCLS006 (Furosemide)Vehicle
Started246238
Subjects who had 1 wart118117
Subjects who had 2 warts5653
Subjects who had 3 warts2424
Subjects who had 4 warts2112
Subjects who had 5 warts1211
Subjects who had 6 warts1521
Completed229214
Not completed1724

Outcome measures

PrimaryDifference in the Proportion of Subjects With Complete Clearance of All Treated Warts Between the Active and Vehicle at Week 18/End of Post-treatment Efficacy Evaluation.
Time frame:
Week 18
Reported as:
Count of participants · Participants
Difference in the Proportion of Subjects With Complete Clearance of All Treated Warts Between the Active and Vehicle at Week 18/End of Post-treatment Efficacy Evaluation.
ParticipantsCLS006 (Furosemide)Vehicle
Achieved complete clearance of all treated warts3224
Not achieved complete clearance of all treated warts197190
Statistical analysis
  • CLS006 (Furosemide) · Cochran-Mantel-Haenszel · p = 0.1789
SecondaryThe Ratio of the Number of Cleared Warts Out of the Number of Treated Warts for Each Subject
Time frame:
Week 18
Reported as:
Mean · ratio of cleared warts
The Ratio of the Number of Cleared Warts Out of the Number of Treated Warts for Each Subject
ratio of cleared wartsCLS006 (Furosemide)Vehicle
The Ratio of the Number of Cleared Warts Out of the Number of Treated Warts for Each Subject0.178 ± 0.36360.145 ± 0.3334
SecondaryDifference in the Proportion of Subjects With Complete Clearance of All Treated Warts at Week 12.
Time frame:
Week 12
Reported as:
Count of participants · Participants
Difference in the Proportion of Subjects With Complete Clearance of All Treated Warts at Week 12.
ParticipantsCLS006 (Furosemide)Vehicle
Complete clearance of all treated warts2114
Not complete clearance of all treated warts208200
SecondaryThe Ratio of Cleared Warts to All Treated Warts for Each Subject at Week 12
Time frame:
Week 12
Reported as:
Mean · ratio of cleared warts
The Ratio of Cleared Warts to All Treated Warts for Each Subject at Week 12
ratio of cleared wartsCLS006 (Furosemide)Vehicle
The Ratio of Cleared Warts to All Treated Warts for Each Subject at Week 120.120 ± 0.30410.087 ± 0.2601
SecondaryChange From Baseline in Wart Size for Each Subject
Time frame:
Week 18
Reported as:
Mean · mm
Change From Baseline in Wart Size for Each Subject
mmCLS006 (Furosemide)Vehicle
Change From Baseline in Wart Size for Each Subject-2.5 ± 7.13-2.4 ± 6.64

Adverse events

Collected over 18 weeks. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CLS006 (Furosemide)0/246 (0%)0/246 (0%)9/246 (3.7%)
Vehicle0/238 (0%)0/238 (0%)9/238 (3.8%)
Most frequent other events
Most frequent other events
EventCLS006 (Furosemide)Vehicle
Upper respiratory tract infectionInfections and infestations5/2462/238
SinusitisInfections and infestations1/2464/238
HeadacheNervous system disorders3/2463/238

Baseline characteristics

Age, Continuous
Age, Continuous(years)CLS006 (Furosemide)VehicleTotal
Mean28.6 ± 16.4029.1 ± 16.5728.8 ± 16.47
Age, Customized
Age, Customized(Participants)CLS006 (Furosemide)VehicleTotal
>=2 to <12433780
>=12 to <18414384
>=18 to <65158154312
>=65448
Sex: Female, Male
Sex: Female, Male(Participants)CLS006 (Furosemide)VehicleTotal
Female105101206
Male141137278
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CLS006 (Furosemide)VehicleTotal
Hispanic or Latino393978
Not Hispanic or Latino205199404
Unknown or Not Reported202
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CLS006 (Furosemide)VehicleTotal
American Indian or Alaska Native000
Asian314
Native Hawaiian or Other Pacific Islander033
Black or African American121022
White226221447
More than one race000
Unknown or Not Reported538
08

Study locations

30 sites
  • Mobile, Alabama 36608, United States
  • Glendale, Arizona 85308, United States
  • Los Angeles, California 90045, United States
  • Santa Monica, California 90404, United States
  • Santa Rosa, California 95403, United States
  • Denver, Colorado 80220, United States
  • Miami, Florida 33137, United States
  • North Miami Beach, Florida 33162, United States
  • Ormond Beach, Florida 32174, United States
  • Tampa, Florida 33624, United States
  • Plainfield, Indiana 46168, United States
  • Lake Charles, Louisiana 70605, United States
  • Monroe, Louisiana 71203, United States
  • Hunt Valley, Maryland 21030, United States
  • Beverly, Massachusetts 01915, United States
  • Fort Gratiot, Michigan 480059, United States
  • Omaha, Nebraska 68144, United States
  • Portsmouth, New Hampshire 03801, United States
  • New York, New York 10022, United States
  • High Point, North Carolina 27262, United States
  • Wilmington, North Carolina 28405, United States
  • Fort Washington, Pennsylvania 19034, United States
  • Hazleton, Pennsylvania 18201, United States
  • Austin, Texas 78759, United States
  • College Station, Texas 77845, United States
  • Katy, Texas 77494, United States
  • San Antonio, Texas 78213, United States
  • San Antonio, Texas 78229, United States
  • Salt Lake City, Utah 84117, United States
  • Lynchburg, Virginia 24501, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2017, a primary completion of Apr 2018 and a completion of Jul 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2023, 5 years 4 months after primary completion. A results delay was requested in Apr 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2016
First posted
Nov 23, 2016
Start
Jan 2017
Primary completionActual
Apr 16, 2018
CompletionActual
Jul 10, 2018
Results delay requested
Apr 16, 2019
Results first posted
Sep 14, 2023
Last update
Sep 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02971891
Lead sponsor
Maruho Co., Ltd.
Responsible party
Sponsor
First posted
Nov 23, 2016
Start date
Jan 2017
Primary completion
Apr 16, 2018
Completion
Jul 10, 2018
Results posted
Sep 14, 2023
Last update
Sep 14, 2023
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Furosemide

Start the discussion